Kopran surges 11.5 per cent on the BSE

The USFDA had been inspecting the active pharmaceutical ingredients (API) manufacturing facility of Kopran Research Laboratories Ltd at Madad from January 21 to 25, 2019. 

Kopran Ltd. has informed that the inspection has been completed without issuance of any observation under 483. Once DMFs are filed and approved, the company will be able to commence supplies of APIs to the US market. It has already filed the DMF of Atenolol, which is already reviewed and active. 

On January 21, the company reported its Q3FY19 earnings. Its consolidated revenue was up by 11.8 per cent YoY to Rs 105.49 crore. EBITDA grew by 31.6 per cent YoY, while the EBITDA margin jumped from 9.8 per cent to 15.1 per cent. PAT for the quarter grew by 10.8 per cent YoY from Rs 9.8 crore to Rs 10.8 crore. 

The stock of Kopran Ltd. had closed at Rs 41.25 on Thursday. On Friday, it opened at Rs 41.50 and surged 11.5 per cent to hit intra-day high of Rs 46. It closed at Rs 44.65 on the BSE. 

Kopran Ltd. is currently an integrated pharmaceutical company manufacturing a large range of products. It manufactures both APIs and finished dosage forms.